Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals

Pharm World Sci. 1999 Dec;21(6):270-1. doi: 10.1023/a:1008719108916.

Abstract

To assess whether physicians comply with American Society of Clinical Oncology (ASCO) guidelines for the use of CSFs, a prospective survey was performed in 15 Paris university hospitals involved in cancer treatment in 1997. If 45% of the prescriptions complied with the guidelines, primary prophylactic administration, which represented 52% of cases, did not comply with ASCO guidelines. These results suggested that primary prophylactic administration was one major clinical situation in which physicians could benefit from guidance to use a CSFs and that criteria defined by ASCO to allow primary prophylactic administration were not applied in clinical practice.

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Colony-Stimulating Factors / therapeutic use*
  • Drug Utilization
  • Female
  • Guidelines as Topic*
  • Hematinics / therapeutic use*
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications
  • Neutropenia / chemically induced*
  • Neutropenia / prevention & control*
  • Paris
  • Recombinant Proteins / therapeutic use
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Colony-Stimulating Factors
  • Hematinics
  • Recombinant Proteins